Company / Return on Equity (ROE)
LIPELLA PHARMACEUTICALS INC. Return on Equity (ROE) History
FY2022-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-261.3%
FY2024
5-year range
-261.3% / -55.6%
FY2022-FY2024
Trend
-77.9%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
LIPELLA PHARMACEUTICALS INC. reports negative total equity of -261.3% in FY2024. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-261.3% in FY2024.
Declined from -55.6% to -261.3% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -
- 5-Year Change
- -
- 10-Year Change
- -
Key checks
Key Insights
- In FY2024, return on equity (roe) decreased 77.9% year-over-year.
Company context
Key Data Points
- Altman Z-Score -8.99 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | -261.3% | -77.9% |
| FY2023 | -146.9% | -164.4% |
| FY2022 | -55.6% | - |
As of FY2024 · SEC Form 10-K · Last checked Jun 29, 2026